Evaluation of Factors in Human Brain Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

800 participants

Study Classification

OBSERVATIONAL

Study Start Date

1979-07-31

Study Completion Date

2005-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Presently, patients with primary malignant brain tumors have a life expectancy of 15 weeks following surgery unless they receive additional types of therapy (chemotherapy, radiotherapy, and/or immunotherapy). Patients that receive additional therapy can increase life expectancy to 50 weeks.

The statistics on the life expectancy and survival have increased efforts among researchers to develop new treatments for primary malignant brain tumors.

This research project involves the growth and study of human brain tumor cells outside the body in the laboratory as part of an attempt to better understand these tumors and to develop more effective treatments for them.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Preclinical Brain Tumor Models

NCT06045065

Brain Metastases Diffuse Gliomas

UNKNOWN

Improving Survivorship and Health-related Quality of Life in Patients With Primary Brain Tumours

NCT06014398

Hypopituitarism Radiotherapy-Induced Hypopituitarism Brain Tumor

UNKNOWN NA

Natural History of and Specimen Banking for People With Tumors of the Central Nervous System

NCT02851706

Brain Cancer Brain Tumor Spine Cancer +2 more

COMPLETED

Natural History of Patients With Brain and Spinal Cord Tumors

NCT00009035

Astrocytoma Oligodendroglioma Glioblastoma +2 more

COMPLETED

Detecting Malignant Brain Tumor Cells in the Bloodstream During Surgery to Remove the Tumor

NCT00001148

Astrocytoma Glioblastoma Glioma

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This protocol involves the study of human brain tumor cells outside the body in the laboratory as part of an attempt to better understand these tumors and to develop more effective therapeutic measures.

Malignant primary brain tumor patients at present have a life expectancy of approximately 15 weeks following surgery unless other adjunctive measures are taken. With currently available adjunctive therapy the life expectancy reaches 50 weeks.

These survival data have spurred extensive efforts to develop new treatment modalities. Radiation, chemotherapy and immunotherapy have been mildly helpful adjuncts but their use has been largely on empirical grounds or on the basis of experimentation on animal tumor models often quite different in nature from human brain tumors.

Our group has sought to develop data upon which to devise new treatment strategies for patients with malignant brain tumors.

The foundation of our approach rests upon the use of in vitro studies of the cell biology of each patient's tumor.

It is our plan to utilize these tumors for in vitro investigation of the immunology, biology, biochemistry and molecular biology of brain tumors. Optimal conventional therapy will be given to the patients as we seek to learn more of how the scientific information obtained can be used to help them.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Brain Neoplasm Glioblastoma Glioma Pituitary Neoplasm

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients to be studied will have either undergone surgical confirmation of a malignant primary brain tumor or be considered likely to have that diagnosis on the basis of diagnostic studies.

They should have survival likelihood of at least three months and be able to comprehend the nature of the proposed program.

Eligible Sex

ALL

Accepts Healthy Volunteers

No